Literature DB >> 18228019

Decreased radioiodine uptake of FRTL-5 cells after (131)I incubation in vitro: molecular biological investigations indicate a cell cycle-dependent pathway.

Birgit Meller1, Erzsébet Gaspar, Wibke Deisting, Barbara Czarnocka, Manfred Baehre, Björn E Wenzel.   

Abstract

PURPOSE: In radioiodine therapy the "stunning phenomenon" is defined as a reduction of radioiodine uptake after diagnostic application of (131)I. In the current study, we established an in vitro model based on the "Fisher rat thyrocyte cell line no. 5" (FRTL-5) to investigate the stunning.
METHODS: TSH-stimulated FRTL-5 cells were incubated with (131)I. Time-dependent (131)I uptake and the viability of FRTL-5 cells were evaluated at 4-144 h after radioiodine application. All data was corrected for number of viable cells, half life and (131)I concentration. Sodium iodide symporter (NIS) and the housekeeping gene (beta-actin, GAPDH) levels were quantified by quantitative polymerase chain reaction (qPCR). Additionally, immunohistochemical staining (IHC) of NIS on the cell membrane was carried out.
RESULTS: FRTL-5 monolayer cell cultures showed a specific maximum uptake of (131)I 24-48 h after application. Significantly decreased (131)I uptake values were observed after 72-144 h. The decrease in radioiodine uptake was correlated with decreasing mRNA levels of NIS and housekeeping genes. In parallel, unlike in controls, IHC staining of NIS on FRTL-5 cells declined significantly after (131)I long-term incubation.
CONCLUSIONS: It could be demonstrated that during (131)I incubation of FRTL-5 cells, radioiodine uptake decreased significantly. Simultaneously decreasing levels of NIS mRNA and protein expression suggest a NIS-associated mechanism. Since mRNA levels of housekeeping genes decreased, too, the reduced NIS expression might be provoked by a cell cycle arrest. Our investigations recommend the FRTL-5 model as a valuable tool for further molecular biological investigations of the stunning phenomenon.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18228019     DOI: 10.1007/s00259-007-0666-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  34 in total

1.  Seeking a radiobiological explanation for thyroid stunning.

Authors:  M Medvedec
Journal:  Eur J Nucl Med       Date:  2001-03

2.  Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients.

Authors:  Frederik A Verburg; Bart de Keizer; Cornelis J M Lips; Pierre M J Zelissen; John M H de Klerk
Journal:  Eur J Endocrinol       Date:  2005-01       Impact factor: 6.664

3.  Cellular effects of beta-particle delivery on vascular smooth muscle cells and endothelial cells: a dose-response study.

Authors:  J Fareh; R Martel; P Kermani; G Leclerc
Journal:  Circulation       Date:  1999-03-23       Impact factor: 29.690

4.  Iodine suppression of iodide uptake in FRTL-5 thyroid cells.

Authors:  E F Grollman; A Smolar; A Ommaya; D Tombaccini; P Santisteban
Journal:  Endocrinology       Date:  1986-06       Impact factor: 4.736

5.  Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.

Authors:  S P Cholewinski; K S Yoo; P S Klieger; R E O'Mara
Journal:  J Nucl Med       Date:  2000-07       Impact factor: 10.057

6.  [Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 2)].

Authors:  M Dietlein; J Dressler; J Farahati; F Grünwald; B Leisner; E Moser; C Reiners; H Schicha; O Schober
Journal:  Nuklearmedizin       Date:  2004-08       Impact factor: 1.379

7.  Decreased uptake after fractionated ablative doses of iodine-131.

Authors:  Hurng-Sheng Wu; Huey-Herng Hseu; Wan-Yu Lin; Shyh-Jen Wang; Yao-Chi Liu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-04       Impact factor: 9.236

8.  Stimulation of iodide uptake by human chorionic gonadotropin in FRTL-5 cells: effects on sodium/iodide symporter gene and protein expression.

Authors:  Franco Arturi; Ivan Presta; Daniela Scarpelli; Jean-Michel Bidart; Martin Schlumberger; Sebastiano Filetti; Diego Russo
Journal:  Eur J Endocrinol       Date:  2002-11       Impact factor: 6.664

9.  [The importance of the radioiodine test for the calculation of the therapeutic dose in benign thyroid diseases].

Authors:  C Nüchel; B Boddenberg; H Schicha
Journal:  Nuklearmedizin       Date:  1993-04       Impact factor: 1.379

10.  Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement.

Authors:  Muammer Urhan; Simin Dadparvar; Ayse Mavi; Mohamed Houseni; Wichana Chamroonrat; Abass Alavi; Susan J Mandel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-26       Impact factor: 10.057

View more
  5 in total

1.  Mean and maximum standardized uptake values in [18F]FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy.

Authors:  Matthias Schmidt; Elfriede Bollschweiler; Markus Dietlein; Stefan P Mönig; Carsten Kobe; Daniel Vallböhmer; Daniel Vallboehmer; Wolfgang Eschner; Arnulf Hölscher; Harald Schicha
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-12-19       Impact factor: 9.236

2.  Correction for hyperfunctioning radiation-induced stunning (CHRIS) in benign thyroid diseases.

Authors:  C Happel; W T Kranert; D Gröner; B Bockisch; A Sabet; I Vardarli; R Görges; K Herrmann; F Grünwald
Journal:  Endocrine       Date:  2020-03-16       Impact factor: 3.633

3.  Thyroid stunning in radioiodine-131 therapy of benign thyroid diseases.

Authors:  Christian Happel; Wolfgang Tilman Kranert; Hanns Ackermann; Ina Binse; Benjamin Bockisch; Daniel Gröner; Ken Herrmann; Frank Grünwald
Journal:  Endocrine       Date:  2018-12-31       Impact factor: 3.633

4.  ⁹⁹mTcO₄--, auger-mediated thyroid stunning: dosimetric requirements and associated molecular events.

Authors:  Béatrice Cambien; Philippe R Franken; Audrey Lamit; Thibault Mauxion; Peggy Richard-Fiardo; Julien Guglielmi; Lydie Crescence; Bernard Mari; Thierry Pourcher; Jacques Darcourt; Manuel Bardiès; Georges Vassaux
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

5.  The effect of prior antithyroid drug use on delaying remission in high uptake Graves' disease following radioiodine ablation.

Authors:  Muthiah Subramanian; Manu Kurian Baby; Krishna G Seshadri
Journal:  Endocr Connect       Date:  2016-01-15       Impact factor: 3.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.